News

News and Press Releases
CFTR Modulators | About the CF Foundation A Message From Our CEO

The CF Foundation has successfully completed a sale of its remaining stake in royalties related to Vertex's CFTR modulators for an upfront payment of $575 million and a potential future payment of $75 million, bringing additional resources to the fight against CF.

| 3 min read
Research | About the CF Foundation CF Foundation Provides Funding to enGene Inc. to Develop Gene Delivery Vehicle

Today, the Cystic Fibrosis Foundation announced that it awarded funding to enGene Inc. to develop a customized vehicle to deliver genetic-based therapies, such as gene therapy and gene editing, into the lung cells of people with cystic fibrosis (CF). Delivering genetic-based therapies to the lungs is a key hurdle to developing effective treatments for all people with CF, including individuals with two nonsense and rare mutations.

| 4 min read
Research | CFTR Modulators Roche Acquires Potential CF Therapies; Plans to Develop Alternatives to CFTR Modulators

Roche has acquired a set of potentiator compounds from Enterprise Therapeutics and intends to study them for the treatment of CF. The Cystic Fibrosis Foundation previously provided funding to Enterprise to develop these potential medicines.

| 3 min read
Clinical Trials Anti-Inflammatory Drug for CF Fails to Meet Goal of Late-Stage Clinical Trial

Corbus Pharmaceuticals reported today that the Phase 2b clinical trial of its potential anti-inflammatory drug lenabasum did not meet its primary objective of decreasing pulmonary exacerbations in people with cystic fibrosis.

| 2 min read
CFTR Modulators | About the CF Foundation | Clinician Resources CF Foundation Leaders Provide Expertise During ICER Public Meeting

On Aug. 27, leaders from the Cystic Fibrosis Foundation, along with several people from the CF community, participated in a virtual public meeting hosted by the Institute for Clinical and Economic Review to provide insights and expertise on the value of CFTR modulators.

| 3 min read
Drug Pipeline FDA Approves Kalydeco for Infants as Young as 4 Months

The U.S. Food and Drug Administration has approved the use of Kalydeco® (ivacaftor) for infants with cystic fibrosis as young as four months who have certain mutations.

| 3 min read
Drug Pipeline | Clinical Trials Vertex Announces Positive Study Results for Trikafta in Children Ages 6-11

Today, Vertex Pharmaceuticals Inc. announced positive Phase 3 clinical trial data for Trikafta® (elexacaftor/tezacaftor/ivacaftor) in children 6-11 years old with cystic fibrosis.

| 2 min read
Drug Pipeline Vertex Asks FDA to Expand CFTR Modulators to Additional Mutations

Vertex Pharmaceuticals Inc. has submitted three supplemental New Drug Applications to the U.S. Food and Drug Administration (FDA) to expand eligibility for Trikafta® (elexacaftor/tezacaftor/ivacaftor), Symdeko® (tezacaftor/ivacaftor and ivacaftor) and Kalydeco® (ivacaftor) to additional rare CFTR mutations.

| 2 min read
Coronavirus (COVID-19) | Care Centers Over 10,000 Home Spirometers Provided for Virtual Care Visits Through CF Foundation Program

The Cystic Fibrosis Foundation has arranged for over 10,000 home spirometers to be provided to care centers to support continued access to high quality, comprehensive care during the COVID-19 pandemic.

| 2 min read
Research | About the CF Foundation | Our Research Approach CF Foundation Awards Nearly $15 Million to Spur Infection Research

Thirty-three new projects are being funded as part of the Foundation's $100 million Infection Research Initiative.

| 4 min read